A potent, first-in-class, oral agent for treatingOsteoarthritis (OA), including those with chronic kidney disease (CKD). This candidate avoids the gastrointestinal (GI), cardiovascular, and renal toxicities of NSAIDs. A high-value secondary indication is Traumatic Brain Injury (TBI), which is strongly supported by extensive research validating sEH as a critical therapeutic target for reducing neuroinflammation and promoting neurological recovery. Successful completion of three Phase 1 trials in healthy volunteers, demonstrating a clean safety and tolerability profile at doses that inhibit sEH activity with improved pharmaceutical properties, strong PK/PD correlation, limited food and drug-drug interactions, and a validated pharmacodynamic biomarker that de-risks future clinical studies.